Overall, TERT promoter mutations are highly frequent in the carcinoma of the vulva (>50%) particularly in HPV-negative tumours were the mutation rate exceeds 90% and coexists with other genetic alterations such as mutations in TP53 (87%), alteration in CDKN2A (67%), and mutations in NOTCH1 and FAT1 (47% each) (Salama et al., 2022). Here, TERT is linked to neoplasm.